Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program
Arcturus Therapeutics is advancing ARCT-810 for OTC deficiency after phase 2 data normalized glutamine and ammonia levels, with $191.5…
C. C. Abbott 1 clickNASDAQ
Arcturus Therapeutics Holdings Inc.
ARCT
1 story
$270M Market cap · 2026-11-03
Get ARCT news in Claude, ChatGPT or your own code. See plans
C. C. Abbott 1 click